留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

三阴性乳腺癌临床治疗进展

李林容 李炎 孙强

李林容, 李炎, 孙强. 三阴性乳腺癌临床治疗进展[J]. 协和医学杂志, 2023, 14(1): 177-183. doi: 10.12290/xhyxzz.2022-0085
引用本文: 李林容, 李炎, 孙强. 三阴性乳腺癌临床治疗进展[J]. 协和医学杂志, 2023, 14(1): 177-183. doi: 10.12290/xhyxzz.2022-0085
LI Linrong, LI Yan, SUN Qiang. Clinical Trials and Current Progress in the Treatment of Triple-negative Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 177-183. doi: 10.12290/xhyxzz.2022-0085
Citation: LI Linrong, LI Yan, SUN Qiang. Clinical Trials and Current Progress in the Treatment of Triple-negative Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 177-183. doi: 10.12290/xhyxzz.2022-0085

三阴性乳腺癌临床治疗进展

doi: 10.12290/xhyxzz.2022-0085
基金项目: 

中国医学科学院医学与健康科技创新工程 2022-I2M-C & T-B-001

详细信息
    通讯作者:

    孙强, E-mail: sunqiang_pumch@sina.com

  • 中图分类号: R737.9, R-1

Clinical Trials and Current Progress in the Treatment of Triple-negative Breast Cancer

Funds: 

Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences 2022-I2M-C & T-B-001

More Information
  • 摘要: 本文对近年来三阴性乳腺癌(triple-negative breast cancer, TNBC)在手术、放疗、化疗、靶向治疗、免疫治疗等方面的临床研究进展进行回顾和总结,以期对临床实践有所裨益。手术治疗方面,符合适应证的保乳手术和前哨淋巴结活检成为早期TNBC治疗的主要趋势,而乳房重建将进一步改善全乳切除术后患者的心理状态和生活质量。放疗方面,区域淋巴结照射、术中放疗、大分割放疗、加速局部乳房等方面的进展,将为TNBC的精细化放疗模式提供依据。药物治疗方面,奥拉帕利、戈沙妥珠单抗、艾立布林、优替德隆、帕博利珠单抗等药物在TNBC治疗中取得突破性进展。随着对肿瘤免疫机制和发病机制的深入研究,精准治疗和药物临床试验不断发展,TNBC患者的预后和生活质量将得到进一步改善。
    作者贡献:李林容负责论文撰写;孙强、李炎负责选题及论文修订。
    利益冲突:所有作者均声明不存在利益冲突
  • [1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71: 209-249. doi:  10.3322/caac.21660
    [2] Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update[J]. J Clin Oncol Off J Am Soc Clin Oncol, 2018, 36: 2105-2122. doi:  10.1200/JCO.2018.77.8738
    [3] Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer[J]. J Clin Oncol, 2010, 28: 2784-2795. doi:  10.1200/JCO.2009.25.6529
    [4] Foulkes WD, Smith IE, Reis-Filho JS. Triple-Negative Breast Cancer[J]. N Engl J Med, 2010, 363: 1938-1948. doi:  10.1056/NEJMra1001389
    [5] Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathological Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network[J]. Cancer, 2012, 118: 5463-5472. doi:  10.1002/cncr.27581
    [6] Liedtke C, Mazouni C, Hess KR, et al. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer[J]. J Clin Oncol, 2016, 26: 1275-1281.
    [7] Ma D, Chen SY, Ren JX, et al. Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer[J]. J Natl Cancer Inst, 2021, 113: 884-892. doi:  10.1093/jnci/djaa175
    [8] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31: 770-856. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202110015.htm
    [9] Dai C, Miller JA, Shah CS, et al. Clinical Outcomes Following Breast-Conserving Therapy Versus Mastectomy for T1-2N0 Triple-Negative Breast Cancer[J]. Int J Radiat Oncol, 2016, 96: E3.
    [10] Chu QD, Hsieh MC, Lyons JM, et al. 10-Year Survival after Breast-Conserving Surgery Compared with Mastectomy in Louisiana Women with Early-Stage Breast Cancer: A Population-Based Study[J]. J Am Coll Surg, 2021, 232: 607-621. doi:  10.1016/j.jamcollsurg.2020.11.011
    [11] Li H, Chen Y, Wang X, et al. T1-2N0M0 Triple-Negative Breast Cancer Treated With Breast-Conserving Therapy Has Better Survival Compared to Mastectomy: A SEER Population-Based Retrospective Analysis[J]. Clin Breast Cancer, 2019, 19: e669-e682. doi:  10.1016/j.clbc.2019.05.011
    [12] William JG, Meena SM, Jame A, et al. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021[J]. Natl Compr Canc Netw, 2021, 19: 484-493. doi:  10.6004/jnccn.2021.0023
    [13] Wu ZY, Han J, Kim HJ, et al. Breast cancer outcomes following immediate breast reconstruction with implants versus autologous flaps: a propensity score-matched study[J]. Breast Cancer Res Treat, 2022, 191: 365-373. doi:  10.1007/s10549-021-06350-0
    [14] Wu ZY, Kim HJ, Lee JW, et al. Long-term Oncologic Outcomes of Immediate Breast Reconstruction vs Conventional Mastectomy Alone for Breast Cancer in the Setting of Neoadjuvant Chemotherapy[J]. JAMA Surg, 2020, 155: 1142-1150. doi:  10.1001/jamasurg.2020.4132
    [15] Flanagan MR, Zabor EC, Romanoff A, et al. A Comparison of Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Implant Breast Reconstruction[J]. Ann Surg Oncol, 2019, 26: 3133-3140. doi:  10.1245/s10434-019-07548-9
    [16] Li Y, Guo J, Sui Y, et al. Quality of Life in Patients with Breast Cancer following Breast Conservation Surgery: A Systematic Review and Meta-Analysis[J]. J Healthc Eng, 2022, 2022: 1-10.
    [17] Garcia-Etienne CA, Mansel RE, Tomatis M, et al. Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice[J]. Breast Edinb Scotl, 2019, 45: 89-96. doi:  10.1016/j.breast.2019.03.002
    [18] Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis[J]. JAMA, 2017, 318: 918-926. doi:  10.1001/jama.2017.11470
    [19] Ortega Expósito C, Falo C, Pernas S, et al. The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials[J]. Breast Cancer Res Treat, 2021, 189: 111-120. doi:  10.1007/s10549-021-06274-9
    [20] Mamtani A, Patil S, Van Zee KJ, et al. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases[J]. Ann Surg Oncol, 2016, 23: 3481-3486. doi:  10.1245/s10434-016-5259-3
    [21] Haque W, Verma V, Farach A, et al. Postmastectomy radiation therapy for triple negative, node-negative breast cancer[J]. Radiother Oncol, 2019, 132: 48-54.
    [22] Qi WX, Cao L, Xu C, et al. Adjuvant regional nodal irradiation did not improve outcomes in T1-2N1 breast cancer after breast-conserving surgery: A propensity score matching analysis of BIG02/98 and BCIRG005 trials[J]. Breast Edinb Scotl, 2020, 49: 165-170. doi:  10.1016/j.breast.2019.11.001
    [23] Orecchia R, Veronesi U, Maisonneuve P, et al. Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial[J]. Lancet Oncol, 2021, 22: 597-608. doi:  10.1016/S1470-2045(21)00080-2
    [24] Offersen BV, Alsner J, Nielsen HM, et al. Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase Ⅲ Trial: The DBCG HYPO Trial[J]. J Clin Oncol, 2020, 38: 3615-3625. doi:  10.1200/JCO.20.01363
    [25] Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial[J]. The Lancet, 2019, 394: 2165-2172. doi:  10.1016/S0140-6736(19)32515-2
    [26] Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy[J]. N Engl J Med, 2017, 376: 2147-2159. doi:  10.1056/NEJMoa1612645
    [27] Li J, Yu K, Pang D, et al. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase Ⅲ Trial[J]. J Clin Oncol, 2020, 38: 1774-1784. doi:  10.1200/JCO.19.02474
    [28] Wang X, Wang SS, Huang H, et al. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial[J]. JAMA, 2021, 325: 50-58. doi:  10.1001/jama.2020.23370
    [29] Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial[J]. J Clin Oncol, 2022, 40: 1051-1058.
    [30] Li Y, Zhou Y, Mao F, et al. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis[J]. Breast Cancer Res Treat, 2020, 179: 533-542. doi:  10.1007/s10549-019-05513-4
    [31] Möbus V, Jackisch C, Lück HJ, et al. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase Ⅲ iddEPC trial[J]. Ann Oncol, 2018, 29: 178-185. doi:  10.1093/annonc/mdx690
    [32] Gray R, Bradley R, Braybrooke J, et al. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials[J]. Lancet, 2019, 393: 1440-1452. doi:  10.1016/S0140-6736(18)33137-4
    [33] Schneeweiss A, Michel LL, Möbus V, et al. Survival analysis of the randomised phase Ⅲ GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer[J]. Eur J Cancer, 2022, 160: 100-111. doi:  10.1016/j.ejca.2021.10.011
    [34] Li ZY, Zhang Z, Cao XZ, et al. Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis[J]. J Int Med Res, 2020, 48: 300060520964340.
    [35] Zhang L, Wu ZY, Li J, et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase Ⅱ trial[J]. Int J Cancer, 2022, 150: 654-662. doi:  10.1002/ijc.33830
    [36] Yu KD, Ye FG, He M, et al. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2020, 6: 1390-1396. doi:  10.1001/jamaoncol.2020.2965
    [37] Mayer IA, Zhao F, Arteaga CL, et al. Randomized Phase Ⅲ Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131[J]. J Clin Oncol, 2021, 39: 2539-2551. doi:  10.1200/JCO.21.00976
    [38] Liu MC, Hillman DW, Frith AE, et al. Randomized phase Ⅲ trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC)[J]. J Clin Oncol, 2020, 38: 1016. doi:  10.1200/JCO.2020.38.15_suppl.1016
    [39] Xu B, Sun T, Zhang Q, et al. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase Ⅲ randomised controlled trial[J]. Ann Oncol, 2021, 32: 218-228. doi:  10.1016/j.annonc.2020.10.600
    [40] Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation[J]. N Engl J Med, 2017, 377: 523-533. doi:  10.1056/NEJMoa1706450
    [41] Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer[J]. Ann Oncol, 2019, 30: 558-566. doi:  10.1093/annonc/mdz012
    [42] Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer[J]. N Engl J Med, 2021, 384: 2394-2405. doi:  10.1056/NEJMoa2105215
    [43] Tung NM, Robson ME, Ventz S, et al. TBCRC 048: Phase Ⅱ Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes[J]. J Clin Oncol, 2020, 38: 4274-4282. doi:  10.1200/JCO.20.02151
    [44] Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer[J]. N Engl J Med, 2019, 380: 741-751. doi:  10.1056/NEJMoa1814213
    [45] Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer[J]. N Engl J Med, 2021, 384: 1529-1541. doi:  10.1056/NEJMoa2028485
    [46] Sun T, Shi Y, Cui J, et al. A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation. [J]. J Clin Oncol, 2021, 39: 1087. doi:  10.1200/JCO.2021.39.15_suppl.1087
    [47] Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer[J]. N Engl J Med, 2018, 379: 2108-2121. doi:  10.1056/NEJMoa1809615
    [48] Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21: 44-59. doi:  10.1016/S1470-2045(19)30689-8
    [49] Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase Ⅲ trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer[J]. Ann Oncol, 2021, 32: 994-1004. doi:  10.1016/j.annonc.2021.05.801
    [50] Gianni L, Huang CF, Egle D, et al. Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study[A]. Cancer Res, 2020, 80: GS3-04.
    [51] Yusof MM, Cescon DW, Rugo HS, et al. 43O Phase Ⅲ KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia[J]. Ann Oncol, 2020, 31: S1257. doi:  10.1016/j.annonc.2020.10.063
    [52] Rugo HS, Cortes J, Cescon DW, et al. KEYNOTE-355: Final results from a randomized, double-blind phase Ⅲ study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic triple-negative breast cancer[A]. Abstract LBA16 (ESMO Congress)[C]. ESMO Congress: 2021.
    [53] Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer[J]. N Engl J Med, 2020, 382: 810-821. doi:  10.1056/NEJMoa1910549
    [54] Schmid P, Cortes J, Dent R, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer[J]. N Engl J Med, 2022, 386: 556-567. doi:  10.1056/NEJMoa2112651
  • 加载中
计量
  • 文章访问数:  528
  • HTML全文浏览量:  65
  • PDF下载量:  141
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-02-25
  • 录用日期:  2022-05-17
  • 网络出版日期:  2022-10-26
  • 刊出日期:  2023-01-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!